Results 151 to 160 of about 260,030 (390)
Hepatology, EarlyView., 2022 Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou +13 more
wiley +1 more source
SELECTIVE INHIBITION OF KRAS SIGNALING BY COMBINATION OF LOW DOSE RAPAMYCIN AND PACLITAXEL IN VIVO
Успехи молекулярной онкологии, 2018 Background. Therapy with compounds potentially capable to block KRAS oncogene signaling pathway is perspective direction in modern oncopharmacology. The aim of current study was to investigate effects of the combined treatment with rapamycin (RAP) and ...
M. N. Yurova +2 more
doaj +1 more source
Mutational Analysis of Uterine Cervical Cancer That Survived Multiple Rounds of Radiotherapy [PDF]
, 2019 学位記番号 ...
Endang, Nuryadi +2 more
core
Discovery of a Potent and Selective TEAD Degrader with Durable Degradation Activity
Advanced Science, EarlyView.KG‐FP‐003, a highly potent TEAD‐YAP PROTAC derived from the patented inhibitor is developed. It selectively degrades endogenous TEAD proteins in HiBiT systems without IMiD‐related off‐target effects. Screening across 867 cancer cell lines revealed broad and superior anti‐tumor activity, highlighting its therapeutic potential through targeted TEAD ...
Linhui Cao +25 more
wiley +1 more source
Proteogenomic characterization of cholangiocarcinoma
Hepatology, EarlyView., 2022 Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng +18 more
wiley +1 more source
Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development. [PDF]
, 2019 Pancreatic ductal adenocarcinoma (PDAC) remains a deadly disease with no efficacious treatment options. PDAC incidence is projected to increase, which may be caused at least partially by the obesity epidemic.
Eibl, Guido, Rozengurt, Enrique
core
Advanced Science, EarlyView.This study unveils ITGA2⁺ tumor cells as key drivers of pediatric thyroid cancer aggressiveness. These cells orchestrate dual oncogenic pathways: GLUT1‐mediated glycolytic reprogramming and M2 macrophage polarization. This metabolic‐immunological crosstalk promotes tumor progression and metastasis.
Zhi‐jun Zhan +11 more
wiley +1 more source
From Bench to Bedside: Emerging Paradigms in CAR‐T Cell Therapy for Solid Malignancies
Advanced Science, EarlyView.This review discusses emerging paradigms in CAR‐T cell therapy for solid tumors, emphasizing strategies to overcome therapeutic barriers through synthetic biology, immune engineering, and combinatorial approaches. It highlights advancements in logic gating, modulation of the immune microenvironment, and innovative cell designs, providing valuable ...
Yang Chen +7 more
wiley +1 more source
, 2014 Kra-Dai (also called Tai-Kadai and Kam-Tai) is a family of approximately 100 languages spoken in Southeast Asia, extending from the island of Hainan, China, in the east to the Indian province of Assam in the west and south to the Malay Peninsula. The term Kra-Dai was suggested in Weera Ostapirat’s 2000 work “Proto-Kra” (Ostapirat 2000, cited under “Kra-
Peter Jenks, Pittayawat Pittayaporn
openaire +1 more source
KRAS Cold Turkey: Using microRNAs to target KRAS-addicted cancer
RNA & DISEASE, 2015 Human cancers are driven by genetic mutations which cause aberrant activation of pro-growth pathways. Although cancers are uniquely dependent on the pro-growth signaling from oncogenic pathways, efforts to directly target these have been largely unsuccessful. One of the most common and drug resistant oncogenic drivers in colon cancer is the GTPase KRAS.
Matthew F. Jones +3 more
openaire +2 more sources